Immunological treatment options for locoregionally advanced head and neck squamous cell carcinoma

International Reviews of Immunology

Volumn 31, Issue 1, 2012, Pages 22-42

  Schutt, Christopher ^a,b   Bumm, Klaus ^a   Mirandola, Leonardo ^a,c,d   Bernardini, Giovanni ^e   Cunha, Nicholas D' ^a   Tijani, Lukman ^a   Nguyen, Diane ^a   Cordero, Joehassin ^a   Jenkins, Marjorie R ^a,c   Cobos, Everardo ^a,c   Kast, W Martin ^f,g   Chiriva Internati, Maurizio ^a,c  

^a TEXAS TECH UNIVERSITY   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^d UNIVERSITY OF MILAN   (Italy)

^e UNIVERSITY OF INSUBRIA   (Italy)

^f UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^g UNIVERSITY OF HAWAII CANCER CENTER   (United States)

Author keywords

Cancer vaccines; CRT; EGFR; HNSCC; HPV

Indexed keywords

ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; BIVATUZUMAB; BIVATUZUMAB MERTANSINE; BIWA 4; CADHERIN 11; CANCER TESTIS ANTIGEN; CANCER VACCINE; CD44V6 ANTIGEN; CETUXIMAB; CISPLATIN; CYTOKINE; DENDRITIC CELL VACCINE; EPIDERMAL GROWTH FACTOR RECEPTOR; FATTY ACID BINDING PROTEIN; FLUOROURACIL; IMMUNOTOXIN; IMMUNOTOXIN MR 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERSTITIAL COLLAGENASE; MACROPHAGE MIGRATION INHIBITION FACTOR; OSTEONECTIN; PACLITAXEL; PLACEBO; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE 3; SIPULEUCEL T; TENASCIN; TRANSCRIPTION FACTOR RUNX2; TUMOR ANTIGEN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACTIVE IMMUNIZATION; ADOPTIVE TRANSFER; ADVANCED CANCER; ALGORITHM; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; CHEMORADIOTHERAPY; EPIDERMOLYSIS; FLU LIKE SYNDROME; GLIOBLASTOMA; HEAD AND NECK CARCINOMA; HUMAN; INTENSITY MODULATED RADIATION THERAPY; METASTASIS; NONHUMAN; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POSTOPERATIVE CARE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RECURRENT CANCER; SKIN DISEASE; SQUAMOUS CELL CARCINOMA; T LYMPHOCYTE; TREATMENT OUTCOME;

ANIMALS; CARCINOMA, SQUAMOUS CELL; CHEMORADIOTHERAPY; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNOTHERAPY; NEOPLASM RECURRENCE, LOCAL;

EID: 84856082393     PISSN: 08830185     EISSN: 15635244     Source Type: Journal    
DOI: 10.3109/08830185.2011.637253     Document Type: Article

References (86)

1. Cognetti DM, Weber RS, Lai SY. Head and neck cancer: an evolving treatment paradigm. Cancer. 2008; 113:1911-1932.
2. Jemal A., Siegel R.,Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008; 58:71-96.
3. Marur S, Forastiere AA. Head and neck cancer: changing epidemiology, diagnosis, and treatment. Mayo Clin Proc. 2008; 83:489-501. (Pubitemid 351536473)
4. Nguyen NP, Chi A, Nguyen LM, et al. Human papillomavirus-associated oropharyngeal cancer: a new clinical entity. QJM. 2010; 103:229-236.
5. Heck JE, Berthiller J, Vaccarella S, et al. Sexual behaviours and the risk of head and neck cancers: a pooled analysis in the International Head and Neck Cancer Epidemiology (INHANCE) consortium. Int J Epidemiol. 2010; 39:166-181.
6. Goon PK, Stanley MA, Ebmeyer J, et al. HPV & head and neck cancer: a descriptive update. Head Neck Oncol. 2009; 1:36.
7. Lallemant B, Evrard A, Combescure C, et al. Clinical relevance of nine transcriptional molecular markers for the diagnosis of head and neck squamous cell carcinoma in tissue and saliva rinse. BMC Cancer. 2009; 9:370.
8. Haddad RI, Shin DM. Recent advances in head and neck cancer. N Engl JMed. 2008; 359:1143-1154.
9. Langer CJ. Targeted therapy in head and neck cancer: state of the art 2007 and review of clinical applications. Cancer. 2008; 112:2635-2645. (Pubitemid 351969206)
10. Pignon JP, Bourhis J, Domenge C, et al. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet. 2000; 355:949-955. (Pubitemid 30148259)
11. Psyrri A, Fountzilas G.Advances in the treatment of locally advanced non-nasopharyngeal squamous cell carcinoma of the head and neck region.Med Oncol. 2006; 23:1-15. (Pubitemid 43787113)
12. Tsao AS, Garden AS, Kies MS, et al. Phase I/II study of docetaxel, cisplatin, and concomitant boost radiation for locally advanced squamous cell cancer of the head and neck. J Clin Oncol. 2006; 24:4163-4169. (Pubitemid 46622294)
13. Fung C, Grandis JR. Emerging drugs to treat squamous cell carcinomas of the head and neck. Expert Opin Emerg Drugs. 2010; 17:17.
14. ShinotoM, Shioyama Y, Sasaki T, et al. Clinical results of definitive chemoradiotherapy for patients with synchronous head and neck squamous cell carcinoma and esophageal cancer. AmJ ClinOncol. 2010; 3:3.
15. Choi BD, Archer GE,Mitchell DA, et al. EGFRvIII-targeted vaccination therapy ofmalignant glioma. Brain Pathol. 2009; 19:713-723.
16. Li G,Mitra S,Wong AJ. The epidermal growth factor variant III peptide vaccine for treatment ofmalignant gliomas. Neurosurg Clin N Am. 2010; 21:87-93.
17. Li G, Wong AJ. EGF receptor variant III as a target antigen for tumor immunotherapy. Expert Rev Vaccines. 2008; 7:977-985.
18. Uribe P, Gonzalez S. Epidermal growth factor receptor (EGFR) and squamous cell carcinoma of the skin:molecular bases for EGFR-targeted therapy. Pathol Res Pract. 2011; 207:337-342.
19. Valentini AM, Pirrelli M, Caruso ML. EGFR-targeted therapy in colorectal cancer: does immunohistochemistry deserve a role in predicting the response to cetuximab? Curr Opin MolTher. 2008; 10:124-131. (Pubitemid 351498874)
20. Wikstr CJ, Hale LP, Batra SK, et al. Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas andmalignant gliomas. Cancer Res. 1995; 55:3140-3148.
21. Tinhofer I, Klinghammer K, Weichert W, et al. Expression of amphiregulin and EGFRvIII affect outcome of patientswith squamous cell carcinoma of the head and neck receiving cetuximab-docetaxel treatment. Clin Cancer Res. 2011; 17:5197-5204.
22. Ochiai H, Archer GE, Herndon JE, 2nd, et al. EGFRvIII-targeted immunotoxin induces antitumor immunity that is inhibited in the absence of CD4+and CD8+T cells. CancerImmunol Immunother. 2008; 57:115-121. (Pubitemid 350043654)
23. Dreier A, Barth S, Goswami A, et al. Cetuximab induces mitochondrial translocalization of EGFRvIII, but not EGFR: involvement of mitochondria in tumor drug resistance? Tumour Biol. 2011; 11:11.
24. Weiner GJ.Monoclonal antibody mechanisms of action in cancer. Immunol Res. 2007; 39:271-278, (Pubitemid 47574893)
25. Baeuerle PA, Kufer P, Bargou R. BiTE: Teaching antibodies to engage T-cells for cancer therapy. Curr OpinMolTher. 2009; 11:22-30.
26. Wolf E, Hofmeister R, Kufer P, et al. BiTEs: bispecific antibody constructs with unique anti-tumor activity. Drug Discov Today. 2005; 10:1237-1244. (Pubitemid 41411434)
27. Lutterbuese R, Schaller E, Burghart E, Sriskandarajah M, Raum T, Rau D, Mangold S, Cierpka R, Guller B, Lutterbuese P, Baeuerle PA, Kufer P. Conversion of cetuximab, panitumumab, trastuzumab andomalizumab intoT-cell- engagingBiTEantibodies createsnovel drug candidates of high potency. Proc Am Assoc Cancer Res. 2008; 99:Abs 2402.
28. Tijink BM, Buter J, R de Bree, et al. A phase I dose escalation study with anti-CD44v6 bivatuzumab mertansine in patients with incurable squamous cell carcinoma of the head and neck or esophagus. Clin Cancer Res. 2006; 12:6064-6072. (Pubitemid 44703770)
29. Sauter A,KloftC,GronauS, et al.Pharmacokinetics,immunogenicity and safety of bivatuzumabmertansine, a novel CD44v6-targeting immunoconjugate, in patients with squamous cell carcinoma of the head and neck. Int J Oncol. 2007; 30:927-935.
30. Van Hal NL, Van Dongen GA, Ten Brink CB, et al. Sequence variation in the monoclonal-antibody- U36-defined CD44v6 epitope. Cancer Immunol Immunother. 1997; 45:88-92. (Pubitemid 27497683)
31. Colnot DR, Ossenkoppele GJ, Roos JC, et al. Reinfusion of unprocessed, granulocyte colonystimulating factor-stimulated whole blood allows dose escalation of 186Relabeled chimeric monoclonal antibody U36 radioimmunotherapy in a phase I dose escalation study. Clin Cancer Res. 2002; 8:3401-3406. (Pubitemid 35340714)
32. Borjesson PK, Postema EJ, Roos JC, et al. Phase I therapy study with (186)Re-labeled humanized monoclonal antibody BIWA 4 (bivatuzumab) in patients with head and neck squamous cell carcinoma. Clin Cancer Res. 2003; 9:3961S-3972S. (Pubitemid 37169203)
33. Mackay CR, Terpe HJ, Stauder R, et al. Expression and modulation of CD44 variant isoforms in humans. J Cell Biol. 1994; 124:71-82. (Pubitemid 24054611)
34. Rupp U, Schoendorf-Holl E, Eichbaum M, et al. Safety and pharmacokinetics of bivatuzumab mertansine in patients with CD44v6-positive metastatic breast cancer: final results of a phase I study. Anticancer Drugs. 2007; 18:477-485. (Pubitemid 46712412)
35. Platt VM, Szoka FC, Jr. Anticancer therapeutics: targeting macromolecules and nanocarriers to hyaluronan or CD44, a hyaluronan receptor.Mol Pharm. 2008; 5:474-486.
36. Rosenberg SA. Overcoming obstacles to the effective immunotherapy of human cancer. Proc Natl Acad Sci U S A. 2008; 105:12643-12644.
37. MChiriva-Internati, Cobos E, KastWM.Advances in immunotherapy ofmultiplemyeloma: from the discovery of tumor-associated antigens to clinical trials. Int Rev Immunol. 2007; 26:197-222. (Pubitemid 46897675)
38. Rapidis AD, Wolf GT. Immunotherapy of head and neck cancer: current and future considerations. J Oncol. 2009; 2009:346345.
39. Chiriva-Internati M, Yu Y, Mirandola L, et al. Cancer testis antigen vaccination affords long-term protection in amurinemodel of ovarian cancer. PLoS One. 2010; 5:e10471.
40. Weinert BT, Krishnadath KK,Milano F, et al. Real-time PCR analysis of genes encoding tumor antigens in esophageal tumors and a cancer vaccine. Cancer Immun. 2009; 9:9.
41. Boni A, Muranski P, Cassard L, et al. Adoptive transfer of allogeneic tumor-specific T cells mediates effective regression of large tumors across major histocompatibility barriers. Blood. 2008; 112:4746-4754.
42. U. S. N. I. o. Health. Clinical Trials. Vol. 2010; 2010.
43. Wolf FWGT, Dolan R. IRX-2: promising new immunotherapy for head and neck cancer. Proceeding of 7th internation Conference on Head and Neck Cancer of American Head and Neck Society. San Francisco, Calif, USA; 2008.
44. Chiriva-InternatiM, Liu Y, Salati E, et al. Efficient generation of cytotoxic T lymphocytes against cervical cancer cells by adeno-associated virus/human papillomavirus type 16 E7 antigen gene transduction into dendritic cells. Eur J Immunol. 2002; 32:30-38. (Pubitemid 34092819)
45. Steinman RM,Mellman I. Immunotherapy: bewitched, bothered, and bewildered nomore. Science. 2004; 305:197-200.
46. Brower V. Approval of provenge seen as first step for cancer treatment vaccines. J Natl Cancer Inst. 2010; 102:1108-1110.
47. Drake CG. Prostate cancer as a model for tumour immunotherapy. Nat Rev Immunol. 2010; 10:580-593.
48. Higano CS, Small EJ, Schellhammer P, et al. Sipuleucel-T. Nat Rev Drug Discov. 2010; 9:513-514.
49. DisisML, Bernhard H, Jaffee EM. Use of tumour-responsive T cells as cancer treatment. Lancet. 2009; 373:673-683.
50. Dudley ME,Wunderlich JR, Yang JC, et al.Adoptive cell transfer therapy followingnon-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol. 2005; 23:2346-2357. (Pubitemid 46218728)
51. GervoisN,Heuze F,Diez E, et al. Selective expansion of a specific anti-tumor CD8+cytotoxic T lymphocyte clone in the bulk culture of tumor-infiltrating lymphocytes froma melanoma patient: cytotoxic activity and T cell receptor gene rearrangements. Eur J Immunol. 1990; 20:825-831. (Pubitemid 20167038)
52. Melief CJ, KastWM. T-cell immunotherapy of cancer. Res Immunol. 1991; 142:425-429.
53. Wong RA, Alexander RB, Puri RK, et al. In vivo proliferation of adoptively transferred tumorinfiltrating lymphocytes in mice. J Immunother. 1991; 10:120-130.
54. Yang JC, Rosenberg SA. Current approaches to the adoptive immunotherapy of cancer. Adv ExpMed Biol. 1988; 233:459-467.
55. Junker N, Andersen MH, Wenandy L, et al. Bimodal ex vivo expansion of T cells from patients with head and neck squamous cell carcinoma: a prerequisite for adoptive cell transfer. Cytotherapy. 2011; 13:822-834.
56. Scholten KB, Turksma AW, Ruizendaal JJ, et al. Generating HPV specific T helper cells for the treatment of HPV inducedmalignancies using TCR gene transfer. J TranslMed. 2011; 9:147.
57. Heemskerk B, Liu K, Dudley ME, et al. Adoptive cell therapy for patients with melanoma, using tumor-infiltrating lymphocytes genetically engineered to secrete interleukin-2. Hum Gene Ther. 2008; 19:496-510. (Pubitemid 351748783)
58. Wrzesinski C, Paulos CM, Kaiser A, et al. Increased intensity lymphodepletion enhances tumor treatment efficacy of adoptively transferred tumor-specific T cells. J Immunother. 2010; 33:1-7.
59. AntonyPA,PiccirilloCA,Akpinarli A, et al.CD8+Tcell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells. J Immunol. 2005; 174:2591-2601. (Pubitemid 40279672)
60. Gillison ML, G D'Souza, Westra W, et al. Distinct risk factor profiles for human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck cancers. J Natl Cancer Inst. 2008; 100:407-420. (Pubitemid 351480511)
61. Rampias T, Sasaki C, Weinberger P, et al. E6 and e7 gene silencing and transformed phenotype of human papillomavirus 16-positive oropharyngeal cancer cells. JNatl Cancer Inst. 2009; 101:412-423.
62. Ang KK,Harris J,Wheeler R, et al.Human papillomavirus and survival of patientswith oropharyngeal cancer. N Engl JMed. 2010; 363:24-35.
63. Fakhry C, Westra WH, Li S, et al. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst. 2008; 100:261-269. (Pubitemid 351480538)
64. Dayyani F, Etzel CJ, Liu M, et al. Meta-analysis of the impact of human papillomavirus (HPV) on cancer risk and overall survival in head and neck squamous cell carcinomas (HNSCC). Head Neck Oncol. 2010; 2:15.
65. Kumar B, Cordell KG, Lee JS, et al. EGFR, p16, HPV Titer, Bcl-xL and p53, sex, and smoking as indicators of response to therapy and survival in oropharyngeal cancer. J Clin Oncol. 2008; 26:3128-3137.
66. Adelstein DJ, Ridge JA, Gillison ML, et al. Head and neck squamous cell cancer and the human papillomavirus: summary of a National Cancer Institute State of the ScienceMeeting, November 9-10, 2008,Washington, D.C. Head Neck. 2009; 31:1393-1422.
67. Munoz N, Manalastas R Jr, Pitisuttithum P, et al. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial. Lancet. 2009; 373:1949-1957.
68. Paavonen J, Naud P, Salmeron J, et al. Efficacy of human papillomavirus (HPV)-16/18 AS04- adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet. 2009; 374: 301-314.
69. Schwarz TF, Spaczynski M, Schneider A, et al. Immunogenicity and tolerability of an HPV-16/18 AS04-adjuvanted prophylactic cervical cancer vaccine in women aged 15-55 years. Vaccine. 2009; 27:581-587.
70. Munoz N, Kjaer SK, Sigurdsson K, et al. Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women. J Natl Cancer Inst. 2010; 102:325-339.
71. Palefsky JM. Human Papillomavirus-related disease in men: not just a women's issue. J Adolescent Health. 2010; 46:S12-S19.
72. Kaneno R, Shurin GV, Tourkova IL, et al. Chemomodulation of human dendritic cell function by antineoplastic agents in low noncytotoxic concentrations. J TranslMed. 2009; 7:58.
73. Gelbard A, Garnett CT, Abrams SI, et al. Combination chemotherapy and radiation of human squamous cell carcinoma of the head and neck augments CTL-mediated lysis. Clin Cancer Res. 2006; 12:1897-1905.
74. Grubeck-Loebenstein B,Della Bella S, Iorio AM, et al. Immunosenescence and vaccine failure in the elderly. Aging Clin Exp Res. 2009; 21:201-209.
75. Shurin MR, Shurin GV, Chatta GS. Aging and the dendritic cell system: implications for cancer. Crit Rev Oncol Hematol. 2007; 64:90-105. (Pubitemid 47488893)
76. Ressing ME, van Driel WJ, Brandt RM, et al. Detection of T helper responses, but not of human papillomavirus-specific cytotoxic T lymphocyte responses, after peptide vaccination of patientswith cervical carcinoma. J Immunother. 2000; 23:255-266. (Pubitemid 30165175)
77. van Driel WJ, Ressing ME, Kenter GG, et al. Vaccination with HPV16 peptides of patients with advanced cervical carcinoma: clinical evaluation of a phase I-II trial. Eur J Cancer. 1999; 35:946-952. (Pubitemid 29277130)
78. Warrino DE, Olson WC, Knapp WT, et al. Disease-stage variance in functional CD4(+) T-cell responses against novel pan-human leukocyte antigen-D region presented human papillomavirus-16 E7 epitopes. Clin Cancer Res. 2004; 10:3301-3308. (Pubitemid 38685434)
79. Dallal RM, LotzeMT. Immunotherapy of metastasis. Surg Oncol Clin N Am. 2001; 10:433-447. (Pubitemid 32472539)
80. Nothelfer EM, Zitzmann-Kolbe S,Garcia-Boy R, et al. Identification and characterization of a peptide with affinity to head and neck cancer. J NuclMed. 2009; 50:426-434.
81. Walsh JE, Lathers DM, Chi AC, et al.Mechanisms of tumor growth and metastasis in head and neck squamous cell carcinoma. Curr Treat Options Oncol. 2007; 8:227-238.
82. Choi P, Jordan CD,Mendez E, et al. Examination of oral cancer biomarkers by tissuemicroarray analysis. Arch Otolaryngol Head Neck Surg. 2008; 134:539-546. (Pubitemid 351724387)
83. Han J, Kioi M, Chu WS, et al. Identification of potential therapeutic targets in human head & neck squamous cell carcinoma. Head Neck Oncol. 2009; 1:27.
84. Lee PS, Teaberry VS, Bland AE, et al. Elevated MAL expression is accompanied by promoter hypomethylation and platinum resistance in epithelial ovarian cancer. Int J Cancer. 2010; 126:1378-1389.
85. Muller-Richter UD, Dowejko A, Reuther T, et al. Analysis of expression profiles ofMAGE-A antigens in oral squamous cell carcinoma cell lines. Head FaceMed. 2009; 5:10.
86. Online CTDatabase. Vol. 2010: Ludwig Institute for Cancer Research; 2010.